Opens in a new tab or window Generalized myasthenia gravis (gMG ... a more stable immunomodulatory effect compared with intravenous immunoglobulin in preventing exacerbations.

Rozanolixizumab is a high-affinity humanized immunoglobulin G4 monoclonal antibody and Fc receptor blocker approved to treat ...

The topic is Myasthenia Gravis ... immunosuppressive drugs, intravenous immunoglobulin therapy. The prognosis for MG is good, some cases go into remission either temporarily or permanently ...

Treatment with inebilizumab was associated with continued improvement in patients with acetylcholine receptor autoantibody-positive (AChR+) generalized myasthenia gravis (gMG), according to 52-week ...

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia ... be used concomitantly with intravenous immunoglobulin and plasma exchange ...

According to Estacio, treatment for myasthenia gravis involves careful use of anticholinesterase and immunosuppresant drugs ...

Generalized myasthenia gravis (gMG ... which may provide a more stable immunomodulatory effect compared with intravenous ...